 Dexiang Gao
Concepts (663)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 22 | 2023 | 2220 | 1.380 |
Why?
| | Head and Neck Neoplasms | 9 | 2023 | 471 | 1.140 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 12 | 2023 | 968 | 1.060 |
Why?
| | Antineoplastic Agents | 17 | 2023 | 1974 | 0.950 |
Why?
| | Melanoma | 9 | 2023 | 664 | 0.910 |
Why?
| | Middle Ear Ventilation | 2 | 2018 | 13 | 0.830 |
Why?
| | Carcinoma, Squamous Cell | 7 | 2022 | 610 | 0.710 |
Why?
| | Small Cell Lung Carcinoma | 5 | 2023 | 83 | 0.700 |
Why?
| | Kidney Neoplasms | 6 | 2021 | 334 | 0.690 |
Why?
| | Forecasting | 2 | 2017 | 353 | 0.660 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 1 | 2018 | 39 | 0.650 |
Why?
| | Carcinoma, Renal Cell | 5 | 2021 | 174 | 0.650 |
Why?
| | Sleep Apnea, Obstructive | 6 | 2019 | 231 | 0.610 |
Why?
| | Protein Kinase Inhibitors | 9 | 2022 | 811 | 0.590 |
Why?
| | DNA Polymerase III | 3 | 2000 | 15 | 0.580 |
Why?
| | Tinnitus | 1 | 2017 | 61 | 0.570 |
Why?
| | Gene Dosage | 5 | 2018 | 136 | 0.560 |
Why?
| | tau Proteins | 3 | 2000 | 78 | 0.560 |
Why?
| | Hearing | 1 | 2017 | 135 | 0.550 |
Why?
| | Humans | 120 | 2023 | 118974 | 0.550 |
Why?
| | Neoplasm Recurrence, Local | 7 | 2023 | 900 | 0.520 |
Why?
| | Primary Health Care | 3 | 2023 | 1560 | 0.520 |
Why?
| | Retrospective Studies | 38 | 2023 | 12978 | 0.500 |
Why?
| | Radiosurgery | 3 | 2023 | 318 | 0.500 |
Why?
| | B7-H1 Antigen | 3 | 2023 | 144 | 0.490 |
Why?
| | Neoplasms | 3 | 2023 | 2179 | 0.480 |
Why?
| | Female | 76 | 2023 | 61565 | 0.450 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 3 | 2018 | 52 | 0.440 |
Why?
| | Brain Neoplasms | 5 | 2023 | 1022 | 0.430 |
Why?
| | Escherichia coli | 3 | 2000 | 758 | 0.430 |
Why?
| | RNA, Messenger | 7 | 2019 | 2657 | 0.430 |
Why?
| | Male | 70 | 2022 | 57801 | 0.420 |
Why?
| | Models, Statistical | 4 | 2019 | 636 | 0.420 |
Why?
| | Neoplasms, Second Primary | 2 | 2023 | 93 | 0.420 |
Why?
| | Cord Blood Stem Cell Transplantation | 4 | 2016 | 96 | 0.410 |
Why?
| | Child, Preschool | 27 | 2019 | 9491 | 0.400 |
Why?
| | Tonsillectomy | 3 | 2019 | 78 | 0.390 |
Why?
| | Gene Expression Profiling | 4 | 2021 | 1597 | 0.390 |
Why?
| | DNA Replication | 3 | 2000 | 211 | 0.390 |
Why?
| | Breast Neoplasms | 5 | 2023 | 1965 | 0.390 |
Why?
| | Databases, Nucleic Acid | 1 | 2010 | 36 | 0.380 |
Why?
| | Bacterial Proteins | 3 | 2000 | 759 | 0.380 |
Why?
| | Radiation Pneumonitis | 2 | 2021 | 26 | 0.370 |
Why?
| | Biomarkers, Tumor | 8 | 2019 | 1059 | 0.370 |
Why?
| | Neoplasm Staging | 10 | 2019 | 1223 | 0.360 |
Why?
| | Myeloid-Derived Suppressor Cells | 2 | 2023 | 57 | 0.350 |
Why?
| | Infant | 19 | 2019 | 8293 | 0.350 |
Why?
| | MicroRNAs | 3 | 2023 | 637 | 0.350 |
Why?
| | Software | 2 | 2011 | 613 | 0.340 |
Why?
| | Surveys and Questionnaires | 4 | 2017 | 4708 | 0.340 |
Why?
| | Down Syndrome | 3 | 2019 | 356 | 0.340 |
Why?
| | Skin Neoplasms | 4 | 2023 | 762 | 0.330 |
Why?
| | Quality of Life | 2 | 2017 | 2366 | 0.330 |
Why?
| | Lymph Nodes | 3 | 2020 | 455 | 0.330 |
Why?
| | Logistic Models | 6 | 2023 | 1901 | 0.320 |
Why?
| | Hematopoietic Stem Cell Transplantation | 4 | 2018 | 540 | 0.310 |
Why?
| | Coronary Artery Bypass | 2 | 2006 | 209 | 0.300 |
Why?
| | Child | 34 | 2023 | 19129 | 0.300 |
Why?
| | Drug Resistance, Neoplasm | 5 | 2016 | 671 | 0.300 |
Why?
| | Pediatrics | 3 | 2019 | 985 | 0.300 |
Why?
| | Aldehyde Dehydrogenase | 3 | 2019 | 134 | 0.300 |
Why?
| | Prostatic Neoplasms | 4 | 2020 | 940 | 0.290 |
Why?
| | Colorectal Neoplasms | 4 | 2016 | 628 | 0.290 |
Why?
| | Oncogenes | 4 | 2022 | 111 | 0.290 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2023 | 1390 | 0.290 |
Why?
| | Mutation | 4 | 2023 | 3457 | 0.280 |
Why?
| | Appointments and Schedules | 1 | 2006 | 78 | 0.280 |
Why?
| | Prognosis | 13 | 2023 | 3443 | 0.280 |
Why?
| | Polysomnography | 4 | 2019 | 157 | 0.280 |
Why?
| | Follow-Up Studies | 12 | 2021 | 4596 | 0.270 |
Why?
| | Survival Analysis | 9 | 2023 | 1267 | 0.270 |
Why?
| | Adolescent | 31 | 2020 | 18480 | 0.270 |
Why?
| | Lymph Node Excision | 2 | 2020 | 158 | 0.270 |
Why?
| | ErbB Receptors | 6 | 2023 | 569 | 0.270 |
Why?
| | Middle Aged | 30 | 2022 | 27617 | 0.260 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 3 | 2021 | 112 | 0.260 |
Why?
| | Pyrazoles | 2 | 2018 | 363 | 0.260 |
Why?
| | Protein-Tyrosine Kinases | 3 | 2022 | 407 | 0.250 |
Why?
| | Immunization | 2 | 2006 | 412 | 0.250 |
Why?
| | Vincristine | 2 | 2022 | 99 | 0.250 |
Why?
| | Tankyrases | 2 | 2016 | 14 | 0.250 |
Why?
| | Hematologic Diseases | 2 | 2016 | 60 | 0.250 |
Why?
| | Child Health Services | 1 | 2006 | 177 | 0.240 |
Why?
| | Postpartum Period | 3 | 2022 | 271 | 0.240 |
Why?
| | Incidence | 8 | 2020 | 2424 | 0.240 |
Why?
| | Continuity of Patient Care | 1 | 2006 | 265 | 0.240 |
Why?
| | Camptothecin | 2 | 2016 | 100 | 0.240 |
Why?
| | Interleukin-2 | 4 | 2023 | 416 | 0.240 |
Why?
| | Sequence Analysis, DNA | 2 | 2021 | 755 | 0.230 |
Why?
| | Pyrroles | 2 | 2016 | 191 | 0.230 |
Why?
| | Quinazolines | 3 | 2016 | 245 | 0.230 |
Why?
| | Receptor, Notch1 | 2 | 2015 | 65 | 0.230 |
Why?
| | Pyridazines | 3 | 2018 | 50 | 0.230 |
Why?
| | Emergency Service, Hospital | 4 | 2012 | 1865 | 0.230 |
Why?
| | Sezary Syndrome | 1 | 2023 | 44 | 0.230 |
Why?
| | Probability | 2 | 2023 | 305 | 0.230 |
Why?
| | Xenograft Model Antitumor Assays | 8 | 2021 | 740 | 0.230 |
Why?
| | Immunotoxins | 1 | 2023 | 35 | 0.230 |
Why?
| | Aged | 23 | 2020 | 19657 | 0.230 |
Why?
| | Adult | 27 | 2023 | 31512 | 0.230 |
Why?
| | Mycosis Fungoides | 1 | 2023 | 62 | 0.230 |
Why?
| | Infratentorial Neoplasms | 1 | 2023 | 50 | 0.230 |
Why?
| | Causality | 1 | 2023 | 109 | 0.230 |
Why?
| | Gene Rearrangement | 3 | 2018 | 141 | 0.220 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 1 | 2023 | 41 | 0.220 |
Why?
| | Urinary Bladder | 2 | 2022 | 180 | 0.220 |
Why?
| | Four-Dimensional Computed Tomography | 2 | 2021 | 27 | 0.220 |
Why?
| | Facial Injuries | 2 | 2015 | 19 | 0.220 |
Why?
| | Cell Proliferation | 8 | 2019 | 2275 | 0.220 |
Why?
| | Facial Bones | 2 | 2015 | 33 | 0.220 |
Why?
| | Graft vs Host Disease | 3 | 2016 | 216 | 0.220 |
Why?
| | Imidazoles | 3 | 2018 | 232 | 0.210 |
Why?
| | Mice | 17 | 2023 | 15520 | 0.210 |
Why?
| | Circulating Tumor DNA | 1 | 2022 | 22 | 0.210 |
Why?
| | Indoles | 2 | 2016 | 316 | 0.210 |
Why?
| | Rhabdomyosarcoma | 1 | 2023 | 57 | 0.210 |
Why?
| | Saliva | 2 | 2018 | 188 | 0.210 |
Why?
| | T-Lymphocytes | 3 | 2017 | 1774 | 0.210 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2022 | 28 | 0.210 |
Why?
| | Cell Line, Tumor | 9 | 2021 | 2851 | 0.210 |
Why?
| | Sarcoma, Ewing | 1 | 2023 | 65 | 0.210 |
Why?
| | Gene Frequency | 1 | 2023 | 513 | 0.210 |
Why?
| | T-Lymphocytes, Regulatory | 3 | 2023 | 359 | 0.210 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2023 | 532 | 0.210 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 2 | 2021 | 120 | 0.210 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2022 | 51 | 0.210 |
Why?
| | Ivermectin | 1 | 2021 | 10 | 0.200 |
Why?
| | Adenocarcinoma | 3 | 2017 | 812 | 0.200 |
Why?
| | Neoplasm Metastasis | 6 | 2020 | 544 | 0.200 |
Why?
| | Ependymoma | 1 | 2023 | 169 | 0.200 |
Why?
| | Lymphatic Metastasis | 6 | 2020 | 307 | 0.200 |
Why?
| | Sarcoma | 1 | 2023 | 137 | 0.200 |
Why?
| | Colonic Polyps | 1 | 2022 | 70 | 0.200 |
Why?
| | Genome | 1 | 2023 | 277 | 0.200 |
Why?
| | Brachytherapy | 1 | 2021 | 103 | 0.200 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2022 | 122 | 0.200 |
Why?
| | Gene Expression Regulation | 1 | 2010 | 2445 | 0.190 |
Why?
| | Diphtheria Toxin | 1 | 2021 | 63 | 0.190 |
Why?
| | Keratin-15 | 1 | 2020 | 14 | 0.190 |
Why?
| | Treatment Outcome | 17 | 2019 | 9342 | 0.190 |
Why?
| | Malaria | 1 | 2021 | 60 | 0.190 |
Why?
| | Proto-Oncogene Proteins c-met | 2 | 2022 | 69 | 0.190 |
Why?
| | Parents | 3 | 2017 | 1212 | 0.190 |
Why?
| | Simulation Training | 1 | 2021 | 66 | 0.190 |
Why?
| | Patient Readmission | 1 | 2006 | 634 | 0.190 |
Why?
| | Cancer Care Facilities | 1 | 2020 | 35 | 0.190 |
Why?
| | Lower Urinary Tract Symptoms | 1 | 2021 | 47 | 0.190 |
Why?
| | Genes, p53 | 1 | 2020 | 64 | 0.190 |
Why?
| | Epidermal Growth Factor | 1 | 2021 | 173 | 0.190 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2020 | 80 | 0.190 |
Why?
| | Postoperative Complications | 5 | 2018 | 2235 | 0.180 |
Why?
| | Orchiopexy | 1 | 2019 | 5 | 0.180 |
Why?
| | Cranial Irradiation | 1 | 2020 | 70 | 0.180 |
Why?
| | Cryptorchidism | 1 | 2019 | 12 | 0.180 |
Why?
| | Androgen Antagonists | 1 | 2020 | 70 | 0.180 |
Why?
| | Doxorubicin | 1 | 2021 | 302 | 0.180 |
Why?
| | Risk Factors | 9 | 2020 | 9000 | 0.180 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2019 | 32 | 0.180 |
Why?
| | DNA Helicases | 1 | 2000 | 131 | 0.180 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2023 | 197 | 0.180 |
Why?
| | In Situ Hybridization, Fluorescence | 3 | 2016 | 310 | 0.180 |
Why?
| | DNA Copy Number Variations | 2 | 2022 | 167 | 0.170 |
Why?
| | Patient Satisfaction | 4 | 2017 | 610 | 0.170 |
Why?
| | Proto-Oncogene Proteins | 2 | 2022 | 618 | 0.170 |
Why?
| | Receptors, Tumor Necrosis Factor, Member 14 | 1 | 2018 | 5 | 0.170 |
Why?
| | Animals | 19 | 2023 | 33381 | 0.170 |
Why?
| | Euterpe | 1 | 2018 | 6 | 0.170 |
Why?
| | Computer Simulation | 1 | 2023 | 922 | 0.170 |
Why?
| | Cleft Lip | 1 | 2018 | 33 | 0.170 |
Why?
| | Urea | 1 | 2019 | 77 | 0.170 |
Why?
| | Papillomavirus Infections | 1 | 2022 | 265 | 0.170 |
Why?
| | Deoxyribonuclease I | 1 | 2018 | 36 | 0.170 |
Why?
| | Pyrimidines | 2 | 2019 | 382 | 0.170 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2021 | 632 | 0.170 |
Why?
| | Colorado | 7 | 2020 | 4196 | 0.170 |
Why?
| | Breast Neoplasms, Male | 1 | 2018 | 31 | 0.160 |
Why?
| | Testicular Neoplasms | 1 | 2019 | 95 | 0.160 |
Why?
| | Cleft Palate | 1 | 2018 | 48 | 0.160 |
Why?
| | Mesenchymal Stem Cell Transplantation | 1 | 2018 | 39 | 0.160 |
Why?
| | Wilms Tumor | 1 | 2019 | 69 | 0.160 |
Why?
| | Anesthesia, General | 1 | 2018 | 48 | 0.160 |
Why?
| | Tubulin Modulators | 1 | 2018 | 10 | 0.160 |
Why?
| | Surgeons | 1 | 2022 | 243 | 0.160 |
Why?
| | Furans | 1 | 2018 | 23 | 0.160 |
Why?
| | Infant, Newborn | 7 | 2018 | 5255 | 0.160 |
Why?
| | Equipment Failure | 1 | 2018 | 114 | 0.160 |
Why?
| | Thromboembolism | 1 | 2018 | 99 | 0.160 |
Why?
| | Posture | 1 | 2018 | 158 | 0.160 |
Why?
| | Ketones | 1 | 2018 | 45 | 0.160 |
Why?
| | Breast | 2 | 2018 | 140 | 0.150 |
Why?
| | Benzamides | 1 | 2018 | 176 | 0.150 |
Why?
| | Otolaryngology | 1 | 2019 | 84 | 0.150 |
Why?
| | Evoked Potentials, Auditory, Brain Stem | 1 | 2018 | 55 | 0.150 |
Why?
| | Abdominal Pain | 1 | 2018 | 133 | 0.150 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2018 | 128 | 0.150 |
Why?
| | Lymphocyte Activation | 3 | 2021 | 1067 | 0.150 |
Why?
| | Cancer Survivors | 1 | 2021 | 201 | 0.150 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 245 | 0.150 |
Why?
| | Calcium-Binding Proteins | 2 | 2015 | 217 | 0.150 |
Why?
| | Abiraterone Acetate | 1 | 2017 | 15 | 0.150 |
Why?
| | Hearing Tests | 1 | 2017 | 49 | 0.150 |
Why?
| | Granulocytes | 1 | 2017 | 79 | 0.150 |
Why?
| | Laryngoscopy | 2 | 2015 | 97 | 0.150 |
Why?
| | Erythrocytes, Abnormal | 1 | 2016 | 16 | 0.150 |
Why?
| | Aurora Kinase B | 1 | 2016 | 9 | 0.150 |
Why?
| | Recurrence | 2 | 2018 | 975 | 0.150 |
Why?
| | Plant Extracts | 1 | 2018 | 165 | 0.150 |
Why?
| | Phosphatidylinositol 3-Kinase | 1 | 2016 | 27 | 0.140 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2018 | 202 | 0.140 |
Why?
| | Pancreatic Cyst | 1 | 2017 | 47 | 0.140 |
Why?
| | Immunotherapy | 1 | 2020 | 493 | 0.140 |
Why?
| | Niacinamide | 2 | 2016 | 70 | 0.140 |
Why?
| | Disease Models, Animal | 4 | 2020 | 3730 | 0.140 |
Why?
| | SOXB1 Transcription Factors | 1 | 2016 | 61 | 0.140 |
Why?
| | Phenylurea Compounds | 2 | 2016 | 85 | 0.140 |
Why?
| | Prednisone | 1 | 2017 | 235 | 0.140 |
Why?
| | Otitis Media | 1 | 2018 | 146 | 0.140 |
Why?
| | In Situ Hybridization | 1 | 2016 | 311 | 0.140 |
Why?
| | Internship and Residency | 2 | 2021 | 1001 | 0.140 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2018 | 164 | 0.140 |
Why?
| | Turbinates | 1 | 2015 | 13 | 0.140 |
Why?
| | Piperazines | 1 | 2018 | 316 | 0.140 |
Why?
| | Hearing Aids | 1 | 2017 | 68 | 0.140 |
Why?
| | Diarrhea | 2 | 2018 | 181 | 0.140 |
Why?
| | Organophosphates | 1 | 2016 | 90 | 0.140 |
Why?
| | Sentinel Lymph Node Biopsy | 2 | 2013 | 118 | 0.140 |
Why?
| | Young Adult | 12 | 2020 | 10793 | 0.130 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2021 | 702 | 0.130 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2016 | 95 | 0.130 |
Why?
| | Prosthesis Implantation | 1 | 2017 | 141 | 0.130 |
Why?
| | Nasal Obstruction | 1 | 2015 | 27 | 0.130 |
Why?
| | Skull Fractures | 1 | 2015 | 30 | 0.130 |
Why?
| | Cetuximab | 1 | 2015 | 99 | 0.130 |
Why?
| | DNA Primers | 3 | 2000 | 533 | 0.130 |
Why?
| | Neovascularization, Pathologic | 2 | 2015 | 287 | 0.130 |
Why?
| | Hematopoietic Stem Cells | 1 | 2018 | 359 | 0.130 |
Why?
| | Prospective Studies | 8 | 2023 | 6471 | 0.130 |
Why?
| | Parotitis | 1 | 2015 | 8 | 0.130 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2015 | 58 | 0.130 |
Why?
| | Trauma Centers | 2 | 2015 | 388 | 0.130 |
Why?
| | Chronic Pain | 1 | 2018 | 211 | 0.130 |
Why?
| | Spleen | 1 | 2017 | 510 | 0.130 |
Why?
| | Microfilament Proteins | 1 | 2015 | 134 | 0.130 |
Why?
| | Interleukin-1 | 1 | 2019 | 980 | 0.130 |
Why?
| | Ribs | 1 | 2014 | 33 | 0.120 |
Why?
| | Efficiency, Organizational | 1 | 2015 | 126 | 0.120 |
Why?
| | Operating Rooms | 1 | 2015 | 90 | 0.120 |
Why?
| | Disease-Free Survival | 5 | 2015 | 649 | 0.120 |
Why?
| | Angiofibroma | 1 | 2013 | 5 | 0.120 |
Why?
| | Spinal Diseases | 1 | 2014 | 47 | 0.120 |
Why?
| | Monocytes | 1 | 2017 | 513 | 0.120 |
Why?
| | Titanium | 1 | 2014 | 67 | 0.120 |
Why?
| | Tumor Microenvironment | 3 | 2022 | 454 | 0.120 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 2013 | 18 | 0.120 |
Why?
| | Disease Progression | 6 | 2018 | 2490 | 0.120 |
Why?
| | DNA Methylation | 1 | 2018 | 503 | 0.120 |
Why?
| | Tumor Cells, Cultured | 4 | 2018 | 874 | 0.120 |
Why?
| | Prosthesis-Related Infections | 1 | 2014 | 73 | 0.120 |
Why?
| | Hearing Loss | 1 | 2017 | 186 | 0.120 |
Why?
| | Health Services Accessibility | 2 | 2012 | 781 | 0.120 |
Why?
| | Ear, External | 1 | 2013 | 24 | 0.120 |
Why?
| | Phosphoproteins | 1 | 2015 | 308 | 0.110 |
Why?
| | Mohs Surgery | 1 | 2013 | 25 | 0.110 |
Why?
| | Binding Sites | 3 | 2000 | 1224 | 0.110 |
Why?
| | Sleep | 1 | 2018 | 660 | 0.110 |
Why?
| | Body Mass Index | 2 | 2019 | 2092 | 0.110 |
Why?
| | Bronchoscopy | 1 | 2015 | 247 | 0.110 |
Why?
| | Bias | 1 | 2014 | 198 | 0.110 |
Why?
| | Protein Binding | 4 | 2011 | 1975 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 4 | 2019 | 842 | 0.110 |
Why?
| | Prostheses and Implants | 1 | 2014 | 141 | 0.110 |
Why?
| | Aged, 80 and over | 7 | 2020 | 6561 | 0.110 |
Why?
| | Apoptosis | 4 | 2018 | 2484 | 0.110 |
Why?
| | Trans-Activators | 1 | 2015 | 373 | 0.110 |
Why?
| | Etomidate | 1 | 2012 | 8 | 0.110 |
Why?
| | United States | 4 | 2023 | 12555 | 0.110 |
Why?
| | RNA, Small Interfering | 2 | 2012 | 564 | 0.110 |
Why?
| | Phenylketonurias | 1 | 2012 | 13 | 0.110 |
Why?
| | Neoplastic Stem Cells | 1 | 2016 | 336 | 0.110 |
Why?
| | Multivariate Analysis | 5 | 2013 | 1474 | 0.110 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2013 | 51 | 0.110 |
Why?
| | Mice, Nude | 4 | 2016 | 663 | 0.110 |
Why?
| | Anesthetics, Intravenous | 1 | 2012 | 34 | 0.110 |
Why?
| | Base Sequence | 3 | 2000 | 2159 | 0.110 |
Why?
| | Hydrocortisone | 3 | 2015 | 273 | 0.110 |
Why?
| | Hemolytic-Uremic Syndrome | 1 | 2012 | 16 | 0.110 |
Why?
| | Myeloid Cells | 1 | 2013 | 128 | 0.110 |
Why?
| | Data Interpretation, Statistical | 1 | 2014 | 336 | 0.110 |
Why?
| | Membrane Proteins | 2 | 2015 | 1055 | 0.110 |
Why?
| | Enzyme Inhibitors | 1 | 2016 | 827 | 0.110 |
Why?
| | Hypothyroidism | 1 | 2012 | 68 | 0.110 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2013 | 91 | 0.110 |
Why?
| | Pediatric Obesity | 1 | 2019 | 524 | 0.110 |
Why?
| | Complementarity Determining Regions | 1 | 2012 | 45 | 0.110 |
Why?
| | Ticlopidine | 1 | 2012 | 61 | 0.100 |
Why?
| | Cytarabine | 1 | 2012 | 53 | 0.100 |
Why?
| | Conscious Sedation | 1 | 2012 | 79 | 0.100 |
Why?
| | Diethylstilbestrol | 1 | 2011 | 9 | 0.100 |
Why?
| | Postoperative Hemorrhage | 1 | 2012 | 79 | 0.100 |
Why?
| | Biomarkers | 3 | 2018 | 3588 | 0.100 |
Why?
| | Epithelial Cells | 2 | 2015 | 963 | 0.100 |
Why?
| | Surgical Wound Infection | 1 | 2014 | 251 | 0.100 |
Why?
| | Wnt Proteins | 1 | 2012 | 140 | 0.100 |
Why?
| | Temporomandibular Joint Dysfunction Syndrome | 1 | 2011 | 4 | 0.100 |
Why?
| | Time Factors | 6 | 2020 | 6412 | 0.100 |
Why?
| | Mandibular Fractures | 1 | 2011 | 11 | 0.100 |
Why?
| | Algorithms | 1 | 2018 | 1541 | 0.100 |
Why?
| | Cancer Vaccines | 1 | 2012 | 139 | 0.100 |
Why?
| | Dance Therapy | 1 | 2010 | 4 | 0.090 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2011 | 136 | 0.090 |
Why?
| | Mice, Inbred NOD | 2 | 2023 | 574 | 0.090 |
Why?
| | Surface Plasmon Resonance | 2 | 2000 | 85 | 0.090 |
Why?
| | Practice Patterns, Physicians' | 1 | 2019 | 1200 | 0.090 |
Why?
| | Signal Transduction | 7 | 2019 | 4709 | 0.090 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2016 | 984 | 0.090 |
Why?
| | Art Therapy | 1 | 2010 | 16 | 0.090 |
Why?
| | Music Therapy | 1 | 2010 | 21 | 0.090 |
Why?
| | Neoadjuvant Therapy | 1 | 2012 | 333 | 0.090 |
Why?
| | Pulmonary Ventilation | 2 | 2021 | 71 | 0.090 |
Why?
| | Benzodioxoles | 1 | 2010 | 84 | 0.090 |
Why?
| | Age Distribution | 2 | 2011 | 362 | 0.090 |
Why?
| | Sex Distribution | 2 | 2011 | 351 | 0.090 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2021 | 1167 | 0.090 |
Why?
| | Dietary Carbohydrates | 1 | 2010 | 153 | 0.090 |
Why?
| | Viremia | 1 | 2009 | 132 | 0.080 |
Why?
| | Dietary Proteins | 1 | 2010 | 130 | 0.080 |
Why?
| | Lung Diseases | 1 | 2015 | 718 | 0.080 |
Why?
| | Chemoradiotherapy | 2 | 2022 | 200 | 0.080 |
Why?
| | Respiratory Syncytial Virus, Human | 1 | 2009 | 61 | 0.080 |
Why?
| | Immunoenzyme Techniques | 3 | 2016 | 195 | 0.080 |
Why?
| | Patient Compliance | 1 | 2012 | 537 | 0.080 |
Why?
| | Parity | 2 | 2022 | 101 | 0.080 |
Why?
| | Adaptive Immunity | 1 | 2009 | 161 | 0.080 |
Why?
| | Neoplasm Transplantation | 2 | 2021 | 245 | 0.080 |
Why?
| | Retinal Dehydrogenase | 2 | 2019 | 40 | 0.080 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2009 | 99 | 0.080 |
Why?
| | Fasting | 2 | 2006 | 264 | 0.080 |
Why?
| | Chronic Disease | 3 | 2016 | 1636 | 0.080 |
Why?
| | Cohort Studies | 5 | 2022 | 5116 | 0.080 |
Why?
| | Cell Cycle Proteins | 1 | 2012 | 565 | 0.080 |
Why?
| | Cytomegalovirus Infections | 1 | 2009 | 187 | 0.080 |
Why?
| | Cluster Analysis | 2 | 2021 | 481 | 0.080 |
Why?
| | Age Factors | 4 | 2019 | 2995 | 0.080 |
Why?
| | Nuclear Proteins | 1 | 2012 | 597 | 0.080 |
Why?
| | Research Design | 3 | 2021 | 969 | 0.070 |
Why?
| | Quality Improvement | 1 | 2015 | 963 | 0.070 |
Why?
| | Outpatients | 1 | 2010 | 325 | 0.070 |
Why?
| | Clinical Competence | 2 | 2021 | 951 | 0.070 |
Why?
| | Immunophenotyping | 2 | 2018 | 278 | 0.070 |
Why?
| | Genomics | 1 | 2012 | 706 | 0.070 |
Why?
| | Adrenal Glands | 1 | 2006 | 72 | 0.070 |
Why?
| | Glucagon | 1 | 2006 | 97 | 0.070 |
Why?
| | Sample Size | 2 | 2021 | 133 | 0.070 |
Why?
| | Diagnosis-Related Groups | 1 | 2006 | 30 | 0.070 |
Why?
| | Femoral Fractures | 1 | 2007 | 67 | 0.070 |
Why?
| | Sequence Analysis, RNA | 2 | 2021 | 409 | 0.070 |
Why?
| | After-Hours Care | 1 | 2006 | 16 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 2 | 2022 | 2436 | 0.070 |
Why?
| | Nerve Block | 1 | 2007 | 67 | 0.070 |
Why?
| | Adenovirus Infections, Human | 1 | 2005 | 14 | 0.070 |
Why?
| | Morphine | 1 | 2007 | 134 | 0.070 |
Why?
| | Cytosine | 1 | 2005 | 46 | 0.070 |
Why?
| | Comorbidity | 2 | 2012 | 1527 | 0.070 |
Why?
| | Specimen Handling | 1 | 2007 | 165 | 0.070 |
Why?
| | Statistics, Nonparametric | 1 | 2006 | 403 | 0.070 |
Why?
| | Wounds, Nonpenetrating | 1 | 2009 | 285 | 0.070 |
Why?
| | Chi-Square Distribution | 1 | 2006 | 525 | 0.070 |
Why?
| | Gene Amplification | 2 | 2016 | 97 | 0.060 |
Why?
| | Aortic Diseases | 1 | 2006 | 94 | 0.060 |
Why?
| | Organophosphonates | 1 | 2005 | 94 | 0.060 |
Why?
| | Confidence Intervals | 3 | 2013 | 324 | 0.060 |
Why?
| | Aortic Valve | 2 | 2006 | 401 | 0.060 |
Why?
| | Immunohistochemistry | 3 | 2015 | 1691 | 0.060 |
Why?
| | Proportional Hazards Models | 2 | 2022 | 1125 | 0.060 |
Why?
| | Glucose Intolerance | 1 | 2006 | 139 | 0.060 |
Why?
| | Risk Assessment | 4 | 2020 | 3057 | 0.060 |
Why?
| | Prostate-Specific Antigen | 2 | 2018 | 156 | 0.060 |
Why?
| | Nausea | 2 | 2018 | 107 | 0.060 |
Why?
| | Ki-67 Antigen | 2 | 2015 | 108 | 0.060 |
Why?
| | Medically Uninsured | 1 | 2005 | 125 | 0.060 |
Why?
| | Insurance Coverage | 1 | 2006 | 208 | 0.060 |
Why?
| | Hospitals, Pediatric | 3 | 2015 | 505 | 0.060 |
Why?
| | Survival Rate | 3 | 2017 | 1720 | 0.060 |
Why?
| | Triglycerides | 1 | 2006 | 519 | 0.060 |
Why?
| | Cause of Death | 1 | 2006 | 380 | 0.060 |
Why?
| | Aorta | 1 | 2006 | 367 | 0.060 |
Why?
| | Immunity, Innate | 1 | 2009 | 745 | 0.060 |
Why?
| | Reoperation | 2 | 2017 | 557 | 0.060 |
Why?
| | Pain Management | 1 | 2007 | 294 | 0.060 |
Why?
| | Teaching | 1 | 2006 | 236 | 0.060 |
Why?
| | Brain Concussion | 1 | 2010 | 470 | 0.060 |
Why?
| | Stress, Physiological | 1 | 2007 | 415 | 0.060 |
Why?
| | Tissue Donors | 1 | 2005 | 336 | 0.060 |
Why?
| | Chromosomes | 1 | 2023 | 87 | 0.060 |
Why?
| | Biopsy | 2 | 2018 | 1079 | 0.060 |
Why?
| | Neoplasm Invasiveness | 2 | 2015 | 462 | 0.060 |
Why?
| | Chromosome Aberrations | 1 | 2023 | 136 | 0.060 |
Why?
| | Antibodies, Monoclonal | 2 | 2023 | 1284 | 0.060 |
Why?
| | Infant, Premature | 1 | 2007 | 480 | 0.060 |
Why?
| | Diabetic Ketoacidosis | 1 | 2005 | 168 | 0.060 |
Why?
| | CTLA-4 Antigen | 1 | 2023 | 86 | 0.060 |
Why?
| | Education, Medical | 1 | 2006 | 239 | 0.060 |
Why?
| | Antigens, CD | 2 | 2016 | 460 | 0.060 |
Why?
| | Response Evaluation Criteria in Solid Tumors | 1 | 2022 | 15 | 0.050 |
Why?
| | Endoscopy | 2 | 2015 | 272 | 0.050 |
Why?
| | Breast Feeding | 1 | 2006 | 386 | 0.050 |
Why?
| | Australia | 1 | 2023 | 212 | 0.050 |
Why?
| | Regression Analysis | 2 | 2019 | 983 | 0.050 |
Why?
| | Tretinoin | 1 | 2023 | 116 | 0.050 |
Why?
| | Pilot Projects | 3 | 2015 | 1419 | 0.050 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2005 | 267 | 0.050 |
Why?
| | Surgical Instruments | 1 | 2022 | 49 | 0.050 |
Why?
| | Urination | 1 | 2022 | 39 | 0.050 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2014 | 333 | 0.050 |
Why?
| | Histocompatibility Testing | 2 | 2016 | 123 | 0.050 |
Why?
| | Reminder Systems | 1 | 2004 | 163 | 0.050 |
Why?
| | Mass Drug Administration | 1 | 2021 | 7 | 0.050 |
Why?
| | Exons | 1 | 2022 | 307 | 0.050 |
Why?
| | Academic Medical Centers | 2 | 2015 | 422 | 0.050 |
Why?
| | Receptor, ErbB-2 | 1 | 2023 | 320 | 0.050 |
Why?
| | Anxiety | 2 | 2023 | 845 | 0.050 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2004 | 189 | 0.050 |
Why?
| | Referral and Consultation | 1 | 2006 | 648 | 0.050 |
Why?
| | Cardiac Surgical Procedures | 1 | 2006 | 461 | 0.050 |
Why?
| | DnaB Helicases | 1 | 2000 | 4 | 0.050 |
Why?
| | Ipilimumab | 1 | 2021 | 29 | 0.050 |
Why?
| | Erlotinib Hydrochloride | 1 | 2021 | 66 | 0.050 |
Why?
| | Chromatography, Affinity | 1 | 2000 | 85 | 0.050 |
Why?
| | Carcinogenesis | 1 | 2022 | 182 | 0.050 |
Why?
| | Transcriptome | 2 | 2016 | 756 | 0.050 |
Why?
| | Pregnancy | 3 | 2022 | 5691 | 0.050 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2020 | 47 | 0.050 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2022 | 229 | 0.050 |
Why?
| | Transplantation, Homologous | 2 | 2016 | 415 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 982 | 0.050 |
Why?
| | Geography | 2 | 2012 | 190 | 0.050 |
Why?
| | Hydrolysis | 1 | 2000 | 176 | 0.050 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2000 | 332 | 0.050 |
Why?
| | Mice, SCID | 1 | 2021 | 333 | 0.050 |
Why?
| | Blotting, Western | 2 | 2014 | 1194 | 0.050 |
Why?
| | Colonoscopy | 1 | 2022 | 208 | 0.050 |
Why?
| | Cells, Cultured | 2 | 2019 | 4077 | 0.050 |
Why?
| | Antiviral Agents | 1 | 2005 | 654 | 0.050 |
Why?
| | Neoplasms, Experimental | 1 | 2020 | 158 | 0.040 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2004 | 325 | 0.040 |
Why?
| | Lactation | 2 | 2014 | 160 | 0.040 |
Why?
| | Obesity | 2 | 2010 | 2746 | 0.040 |
Why?
| | Carbamoyl-Phosphate Synthase (Ammonia) | 1 | 2019 | 6 | 0.040 |
Why?
| | Curriculum | 2 | 2021 | 910 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2014 | 1293 | 0.040 |
Why?
| | Analgesics, Opioid | 1 | 2007 | 794 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2021 | 187 | 0.040 |
Why?
| | Cell Respiration | 1 | 2019 | 76 | 0.040 |
Why?
| | Fruit and Vegetable Juices | 1 | 2018 | 15 | 0.040 |
Why?
| | Influenza Vaccines | 1 | 2004 | 500 | 0.040 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2012 | 770 | 0.040 |
Why?
| | Nitric Oxide | 1 | 2004 | 892 | 0.040 |
Why?
| | Aurora Kinase A | 1 | 2018 | 52 | 0.040 |
Why?
| | Central Nervous System | 1 | 2020 | 245 | 0.040 |
Why?
| | Flow Cytometry | 2 | 2013 | 1085 | 0.040 |
Why?
| | Chinchilla | 1 | 2018 | 38 | 0.040 |
Why?
| | Administration, Topical | 1 | 2018 | 141 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2018 | 245 | 0.040 |
Why?
| | Severity of Illness Index | 3 | 2017 | 2674 | 0.040 |
Why?
| | Transplantation, Heterologous | 1 | 2018 | 194 | 0.040 |
Why?
| | Medical Oncology | 1 | 2020 | 229 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2021 | 554 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2021 | 653 | 0.040 |
Why?
| | Veterans | 2 | 2006 | 1208 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2018 | 269 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2016 | 1945 | 0.040 |
Why?
| | Cell Cycle Checkpoints | 1 | 2018 | 87 | 0.040 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 237 | 0.040 |
Why?
| | Glycolysis | 1 | 2019 | 224 | 0.040 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2019 | 202 | 0.040 |
Why?
| | Area Under Curve | 1 | 2018 | 296 | 0.040 |
Why?
| | Risk | 2 | 2013 | 853 | 0.040 |
Why?
| | Adenoidectomy | 1 | 2017 | 60 | 0.040 |
Why?
| | Erythrocyte Indices | 1 | 2016 | 29 | 0.040 |
Why?
| | Caspase 3 | 1 | 2018 | 243 | 0.040 |
Why?
| | Bone Conduction | 1 | 2017 | 32 | 0.040 |
Why?
| | Tissue Array Analysis | 1 | 2016 | 52 | 0.040 |
Why?
| | Taxoids | 1 | 2017 | 98 | 0.040 |
Why?
| | Tumor Escape | 1 | 2017 | 38 | 0.040 |
Why?
| | Sensitivity and Specificity | 3 | 2006 | 1795 | 0.040 |
Why?
| | Polyploidy | 1 | 2016 | 17 | 0.040 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 1 | 2017 | 41 | 0.040 |
Why?
| | Fatigue | 1 | 2018 | 297 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2019 | 625 | 0.040 |
Why?
| | Genes, myc | 1 | 2016 | 46 | 0.040 |
Why?
| | Axin Protein | 1 | 2016 | 18 | 0.040 |
Why?
| | Unrelated Donors | 1 | 2016 | 38 | 0.040 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 667 | 0.040 |
Why?
| | Transforming Growth Factor beta | 1 | 2019 | 462 | 0.040 |
Why?
| | Hyaluronan Receptors | 1 | 2016 | 93 | 0.040 |
Why?
| | Cell Count | 1 | 2017 | 315 | 0.040 |
Why?
| | Centrosome | 1 | 2016 | 59 | 0.030 |
Why?
| | Spheroids, Cellular | 1 | 2016 | 56 | 0.030 |
Why?
| | Papillomaviridae | 1 | 2016 | 101 | 0.030 |
Why?
| | Administration, Oral | 1 | 2018 | 756 | 0.030 |
Why?
| | Prosthesis Failure | 1 | 2017 | 120 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1244 | 0.030 |
Why?
| | Up-Regulation | 1 | 2019 | 872 | 0.030 |
Why?
| | Jagged-1 Protein | 1 | 2015 | 25 | 0.030 |
Why?
| | Serrate-Jagged Proteins | 1 | 2015 | 30 | 0.030 |
Why?
| | Antigens, Differentiation | 1 | 2015 | 79 | 0.030 |
Why?
| | Maximum Tolerated Dose | 1 | 2015 | 185 | 0.030 |
Why?
| | Tumor Burden | 1 | 2016 | 274 | 0.030 |
Why?
| | Salivary Ducts | 1 | 2015 | 5 | 0.030 |
Why?
| | Genotype | 1 | 2021 | 1882 | 0.030 |
Why?
| | Gene Duplication | 1 | 2015 | 64 | 0.030 |
Why?
| | Clinical Audit | 1 | 2015 | 13 | 0.030 |
Why?
| | Time and Motion Studies | 1 | 2015 | 23 | 0.030 |
Why?
| | Cadherins | 1 | 2016 | 186 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2020 | 2025 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2018 | 1308 | 0.030 |
Why?
| | Angiogenesis Inhibitors | 1 | 2016 | 219 | 0.030 |
Why?
| | Cell Division | 1 | 2016 | 776 | 0.030 |
Why?
| | Hedgehog Proteins | 1 | 2015 | 175 | 0.030 |
Why?
| | Patient Selection | 1 | 2018 | 676 | 0.030 |
Why?
| | Epithelium | 1 | 2015 | 305 | 0.030 |
Why?
| | Mortality | 1 | 2016 | 299 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 1384 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2016 | 317 | 0.030 |
Why?
| | Leukocyte Common Antigens | 1 | 2014 | 76 | 0.030 |
Why?
| | Catheterization | 1 | 2015 | 163 | 0.030 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2014 | 55 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 1 | 2016 | 396 | 0.030 |
Why?
| | Metabolomics | 1 | 2019 | 550 | 0.030 |
Why?
| | Thoracotomy | 1 | 2014 | 84 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2018 | 539 | 0.030 |
Why?
| | Blood Cell Count | 1 | 2013 | 53 | 0.030 |
Why?
| | Premenopause | 1 | 2014 | 108 | 0.030 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2016 | 369 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 1868 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2018 | 1158 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2015 | 369 | 0.030 |
Why?
| | Survivors | 1 | 2016 | 418 | 0.030 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2013 | 88 | 0.030 |
Why?
| | Cell Line | 1 | 2019 | 2707 | 0.030 |
Why?
| | Mitochondria | 1 | 2019 | 786 | 0.030 |
Why?
| | Hypertension, Pulmonary | 1 | 2004 | 1794 | 0.030 |
Why?
| | Angiography | 1 | 2013 | 185 | 0.030 |
Why?
| | Tonsillitis | 1 | 2012 | 7 | 0.030 |
Why?
| | Pain | 2 | 2010 | 735 | 0.030 |
Why?
| | Immune System | 1 | 2014 | 181 | 0.030 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2006 | 2174 | 0.030 |
Why?
| | Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2012 | 20 | 0.030 |
Why?
| | Thyroid Hormones | 1 | 2012 | 55 | 0.030 |
Why?
| | Vinblastine | 1 | 2012 | 68 | 0.030 |
Why?
| | Pharyngitis | 1 | 2012 | 25 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2022 | 4908 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2012 | 3171 | 0.030 |
Why?
| | Biological Therapy | 1 | 2012 | 26 | 0.030 |
Why?
| | Thyroid Gland | 1 | 2012 | 84 | 0.030 |
Why?
| | Dacarbazine | 1 | 2012 | 102 | 0.030 |
Why?
| | Fentanyl | 1 | 2012 | 70 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2018 | 2680 | 0.030 |
Why?
| | S Phase | 1 | 2012 | 74 | 0.030 |
Why?
| | Phosphorylation | 1 | 2016 | 1633 | 0.030 |
Why?
| | Vaccines, Subunit | 1 | 2012 | 42 | 0.030 |
Why?
| | Patient Safety | 1 | 2015 | 281 | 0.030 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2012 | 76 | 0.030 |
Why?
| | Length of Stay | 1 | 2016 | 1032 | 0.030 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2012 | 83 | 0.030 |
Why?
| | Histones | 1 | 2016 | 552 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2015 | 465 | 0.020 |
Why?
| | Temporomandibular Joint | 1 | 2011 | 12 | 0.020 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2012 | 360 | 0.020 |
Why?
| | Interferon-alpha | 1 | 2012 | 191 | 0.020 |
Why?
| | Cisplatin | 1 | 2012 | 271 | 0.020 |
Why?
| | Unconsciousness | 1 | 2010 | 24 | 0.020 |
Why?
| | Brain | 1 | 2022 | 2490 | 0.020 |
Why?
| | Myeloablative Agonists | 1 | 2010 | 22 | 0.020 |
Why?
| | STAT1 Transcription Factor | 1 | 2011 | 69 | 0.020 |
Why?
| | Fracture Healing | 1 | 2011 | 74 | 0.020 |
Why?
| | Amnesia | 1 | 2010 | 46 | 0.020 |
Why?
| | Respiratory Insufficiency | 1 | 2014 | 290 | 0.020 |
Why?
| | Creativity | 1 | 2010 | 8 | 0.020 |
Why?
| | Antigens, Neoplasm | 1 | 2012 | 228 | 0.020 |
Why?
| | Gene Expression | 1 | 2015 | 1489 | 0.020 |
Why?
| | Patient Care Team | 1 | 2015 | 521 | 0.020 |
Why?
| | Head Injuries, Closed | 1 | 2010 | 55 | 0.020 |
Why?
| | Nursing Methodology Research | 1 | 2010 | 44 | 0.020 |
Why?
| | Psychology, Child | 1 | 2010 | 36 | 0.020 |
Why?
| | Fracture Fixation | 1 | 2011 | 81 | 0.020 |
Why?
| | Appetite | 1 | 2010 | 57 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2275 | 0.020 |
Why?
| | Immunoblotting | 1 | 2010 | 307 | 0.020 |
Why?
| | Colonic Neoplasms | 1 | 2012 | 224 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1440 | 0.020 |
Why?
| | Genome, Human | 1 | 2012 | 387 | 0.020 |
Why?
| | Hypertension | 1 | 2018 | 1203 | 0.020 |
Why?
| | Transplantation Conditioning | 1 | 2010 | 156 | 0.020 |
Why?
| | Cell Separation | 1 | 2010 | 296 | 0.020 |
Why?
| | Databases, Factual | 1 | 2014 | 1231 | 0.020 |
Why?
| | Communication | 1 | 2015 | 761 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2012 | 1206 | 0.020 |
Why?
| | Lung | 1 | 2021 | 3664 | 0.020 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2005 | 3360 | 0.020 |
Why?
| | Demography | 1 | 2009 | 274 | 0.020 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2012 | 402 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2019 | 4552 | 0.020 |
Why?
| | Injury Severity Score | 1 | 2011 | 528 | 0.020 |
Why?
| | Focus Groups | 1 | 2010 | 387 | 0.020 |
Why?
| | Family Characteristics | 1 | 2009 | 156 | 0.020 |
Why?
| | Safety | 1 | 2010 | 304 | 0.020 |
Why?
| | Leukemia | 1 | 2010 | 208 | 0.020 |
Why?
| | RNA Polymerase II | 1 | 2011 | 282 | 0.020 |
Why?
| | Radiography | 1 | 2011 | 861 | 0.020 |
Why?
| | Indicator Dilution Techniques | 1 | 2007 | 12 | 0.020 |
Why?
| | Paper | 1 | 2007 | 9 | 0.020 |
Why?
| | Fractures, Bone | 1 | 2012 | 380 | 0.020 |
Why?
| | Adrenal Gland Diseases | 1 | 2006 | 7 | 0.020 |
Why?
| | Hexokinase | 1 | 2006 | 10 | 0.020 |
Why?
| | Dwarfism | 1 | 2006 | 17 | 0.020 |
Why?
| | Pituitary Diseases | 1 | 2006 | 23 | 0.020 |
Why?
| | Killer Cells, Natural | 1 | 2009 | 381 | 0.020 |
Why?
| | Recovery of Function | 1 | 2011 | 604 | 0.020 |
Why?
| | Radioimmunoassay | 1 | 2006 | 165 | 0.020 |
Why?
| | Urban Population | 1 | 2009 | 409 | 0.020 |
Why?
| | Dilatation, Pathologic | 1 | 2006 | 56 | 0.020 |
Why?
| | Attitude to Health | 1 | 2010 | 410 | 0.020 |
Why?
| | Amides | 1 | 2007 | 86 | 0.020 |
Why?
| | Growth Disorders | 1 | 2006 | 77 | 0.020 |
Why?
| | Anesthetics, Local | 1 | 2007 | 85 | 0.020 |
Why?
| | Echocardiography, Doppler | 1 | 2006 | 95 | 0.020 |
Why?
| | Hormones | 1 | 2006 | 135 | 0.020 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2006 | 152 | 0.020 |
Why?
| | Body Composition | 1 | 2010 | 653 | 0.020 |
Why?
| | Cognition Disorders | 1 | 2010 | 529 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2007 | 380 | 0.020 |
Why?
| | Pituitary-Adrenal System | 1 | 2006 | 159 | 0.020 |
Why?
| | Qualitative Research | 1 | 2010 | 953 | 0.020 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2006 | 195 | 0.020 |
Why?
| | Adenoviridae | 1 | 2005 | 191 | 0.020 |
Why?
| | ROC Curve | 1 | 2006 | 473 | 0.020 |
Why?
| | Microbial Sensitivity Tests | 1 | 2005 | 302 | 0.020 |
Why?
| | Sex Factors | 1 | 2010 | 1781 | 0.020 |
Why?
| | Pain Measurement | 1 | 2007 | 469 | 0.020 |
Why?
| | Office Automation | 1 | 2004 | 5 | 0.020 |
Why?
| | Circadian Rhythm | 1 | 2007 | 401 | 0.010 |
Why?
| | Mitral Valve | 1 | 2004 | 91 | 0.010 |
Why?
| | Hyperoxia | 1 | 2004 | 97 | 0.010 |
Why?
| | International Classification of Diseases | 1 | 2004 | 122 | 0.010 |
Why?
| | Vascular Resistance | 1 | 2004 | 356 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2014 | 1798 | 0.010 |
Why?
| | Respiratory Function Tests | 1 | 2004 | 526 | 0.010 |
Why?
| | Administration, Inhalation | 1 | 2004 | 656 | 0.010 |
Why?
| | Diet | 1 | 2010 | 1153 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2013 | 3174 | 0.010 |
Why?
| | Pulmonary Circulation | 1 | 2004 | 424 | 0.010 |
Why?
| | Medicaid | 1 | 2005 | 411 | 0.010 |
Why?
| | Odds Ratio | 1 | 2004 | 996 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 2004 | 1166 | 0.010 |
Why?
| | Hospitalization | 1 | 2009 | 1785 | 0.010 |
Why?
| | Oxygen | 1 | 2004 | 854 | 0.010 |
Why?
| | Mass Screening | 1 | 2006 | 1052 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2007 | 2874 | 0.010 |
Why?
| | Attitude of Health Personnel | 1 | 2006 | 992 | 0.010 |
Why?
| | Hypoxia | 1 | 2004 | 963 | 0.010 |
Why?
| | Blood Glucose | 1 | 2006 | 1939 | 0.010 |
Why?
| | Registries | 1 | 2004 | 1810 | 0.010 |
Why?
|
|
Gao's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|